And that has some implications for the degree of weight loss and also side-effect profile
Exercising its option to exclusively license Nurixs Therapeutics investigational targeted protein degrader molecule NX0479, Gilead paid $20 million with Nurix eligible to receive an additional $425 million in clinical, regulatory, and commercial milestones
Second part results will be announced in 2029
See our retatrutide cost guide for detailed pricing
The Wegovy pill is oral semaglutide, a GLP-1 medicine that the MHRA approved in June 2026 for weight loss
Outre des nauses, il existe aussi des risques plus rares mais plus graves comme des pancratites aiges, qui peuvent survenir mme doses faibles, des troubles biliaires, de rares cas de constipation svre qui peuvent conduire lobstruction intestinale, relve-t-il, pointant aussi un risque accru de cancer de la thyrode aprs plusieurs annes de traitement